6691.5000 35.00 (0.53%)
NSE Nov 10, 2025 15:31 PM
Volume: 418.6K
 

Deven Choksey
We have revised our FY26E/FY27E EPS estimates by -14.9%/-22.7%, respectively, as we factor in subdued growth traction in Generic API segment, lower other income and higher depreciation expenses on account of higher investments in its facilities.
Number of FII/FPI investors decreased from 990 to 897 in Sep 2025 qtr
More from Divi's Laboratories Ltd.
Recommended